Amicus Therapeutics to Present at Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011

CRANBURY, N.J., May 31, 2011 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Matthew R. Patterson, President and Acting Chief Executive Officer, will present a corporate overview at the Jefferies 2011 Global Healthcare Conference in New York, NY on Tuesday, June 7 at 12:15 p.m. ET.

A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days. Participants are encouraged to visit the web site 10 minutes prior to the start of the presentation to register, download and install any necessary software.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus' lead program Amigal(tm) (migalastat HCl) is in Phase 3 for the treatment of Fabry disease.

FOLD-G

SOURCE Amicus Therapeutics

Suggested Articles

The deal gives Clovis the ex-Europe rights to a cancer candidate set to enter the clinic in the second half of next year.

Sethi spent the past four years at AstraZeneca, rising to the post of chief physician scientist at its clinical discovery unit.

Contract research organization PPD is expanding its Richmond, Virginia, lab by adding 200 new staffers and boosting its research capabilities.